Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic ...
In the article that accompanies this editorial, Lu et al 5 conducted a systematic review on the use of instrumental variable (IV) methods in oncology comparative effectiveness research. The main ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback